Search - tctmd.com

Displaying 21 - 39 of 39

Sort: Relevancy | Date

News Industry News

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

October 23, 2012

News Industry News

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

October 23, 2012

News Industry News

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

June 26, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Industry News

Boston Scientific Supports New Clinical Trial to Evaluate Platinum Chromium Coronary Stents in Treating Heart Attack Patients

March 26, 2012

News Industry News

Paclitaxel-coated balloon angioplasty demonstrates superior results

November 10, 2011

News Industry News

Low CV Event Rate Prompts Closure of Prasugrel Trial

November 09, 2011

News Industry News

Tailored therapy for anti-platelet drugs using a novel point-of-care genetic test provides improved response to medications compared to current standard of care

November 08, 2011

News Industry News

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

November 08, 2011

News Industry News

First clinical trial of point-of-care DNA testing in medicine enables cardiac stent patients to receive personalized antiplatelet therapy

November 08, 2011

News Industry News

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

November 08, 2011

News Industry News

Three-Year Clinical Outcomes from Use of GenousTM Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy

November 07, 2011

News Industry News

Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study

August 15, 2011

News Industry News

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

July 20, 2011

News Industry News

Health Canada approves BRILINTA (ticagrelor tablets)

June 01, 2011

News Industry News

A Prospective, Randomised and Multicentre Trial Comparing Titan2 Bio Active Stent (BAS) and Xience V Drug Eluting Stent (DES): The BASE-ACS Trial

May 17, 2011

News Industry News

On-X Heart Valve PROACT Trial Preliminary Report Provides Evidence Toward Maintaining Patients With Less Warfarin

April 05, 2011

News Industry News

Positive Long-term Safety and Efficacy Demonstrated for OrbusNeich's GenousTM Stent in Large, Unselected Patient Population with Mostly Complex Lesions and Estimated High Risk for Restenosis

March 28, 2011

News Industry News

2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery

March 08, 2011

Advertisement

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Boston Scientific Supports New Clinical Trial to Evaluate Platinum Chromium Coronary Stents in Treating Heart Attack Patients

Paclitaxel-coated balloon angioplasty demonstrates superior results

Low CV Event Rate Prompts Closure of Prasugrel Trial

Tailored therapy for anti-platelet drugs using a novel point-of-care genetic test provides improved response to medications compared to current standard of care

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

First clinical trial of point-of-care DNA testing in medicine enables cardiac stent patients to receive personalized antiplatelet therapy

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

Three-Year Clinical Outcomes from Use of GenousTM Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy

Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

Health Canada approves BRILINTA (ticagrelor tablets)

A Prospective, Randomised and Multicentre Trial Comparing Titan2 Bio Active Stent (BAS) and Xience V Drug Eluting Stent (DES): The BASE-ACS Trial

On-X Heart Valve PROACT Trial Preliminary Report Provides Evidence Toward Maintaining Patients With Less Warfarin

Positive Long-term Safety and Efficacy Demonstrated for OrbusNeich's GenousTM Stent in Large, Unselected Patient Population with Mostly Complex Lesions and Estimated High Risk for Restenosis

2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content